PHARMACOLOGICAL AND CLINICAL ASPECTS OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
Keywords:
phosphodiesterase type 5 inhibitors, erectile dysfunction, pharmacokinetics, pharmacodynamics, side effectsAbstract
Erectile dysfunction (ED) is an important health problem in men associated with reduced quality of life. Implementation of phosphodiesterase type 5 inhibitors (PDE-5 Is) has revolutionized the management of patients with ED and PDE-5Is are currently considered first-line therapy of ED. This paper describes characteristics of the pharmacokinetics, pharmacodynamics and possible clinical side effects of medications from the PDE-5 Is group. PDE-5Is discussed in the article include sildenafil, tadalafil, vardenafil, udenafil, avanafil, lodenafil, mirodenafil, youkenafil, SLx-2101 and simmerafil.
References
Wylie K. Erectile dysfunction. Adv Psychosom Med. 2008;29:33-49.
Chaly M.E., Akhvlediani N.D., Kharchilava R.R. Erectile disfunction. Russian clinical guidelines. Urology. 2017; 2 (Appendix 2): 20-30 (in Russ).
Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32(4):379-95.
Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014 May 14;10:341-54.
Pastuszak AW. Current Diagnosis and Management of Erectile Dysfunction. Curr Sex Health Rep. 2014;6(3):164-176.
Lue T.F. Erectile dysfunction. N Engl J Med. 2000 Jun 15;342(24):1802-13.
McVary K.T. Erectile dysfunction. New Engl. J. Med. 2007; 357: 2472-2481.
Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, Maggi M, Nelson CJ, Parish S, Salonia A, Tan R, Mulhall JP, Hellstrom WJ. Erectile dysfunction. Nat Rev Dis Primers. 2016 Feb 4;2:16003.
Perelman MA. The impact of relationship variables on the etiology, diagnosis and treatment of erectile dysfunction. Adv Primary Care Med: Clin Updat. 2007;3:3-6.
Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130–71.
Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and metaanalysis. Ann Intern Med. 2009;151(9):650-61.
Gafarov R.R., Shodmonova Z.R., Allazov S.A., Xamroev G.A., Tuxtaev F.M. Phosphodiesterase type 5 inhibitors - first line of treatment for erectile dysfunction. Achievements of science and education. 2020;5(59):103-108 (in Russ).
JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
Damulin I.V., Esilevskij Ju.M. Erectile dysfunction: current state of the problem. Urologija, 2014; 3: 95-101 (in Russ).
Chen L, Staubli SE, Schneider MP, Kessels AG, Ivic S, Bachmann LM, Kessler TM. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015 Oct;68(4):674-80.
Gafarov R.R., Bobokulov N.A., & Fayziev Kh.F. Phosphodiesterase type 5 inhibitors - side effects and adverse events associated with use. European journal of molecular medicine. 2024;4(1):40-45 (in Russ).
Grigoryan V.A., Gazimiev M.A., Demidko Yu.L., Baiduvaliev A.M. Sildenafil dosage forms for the treatment of erectile dysfunction. Urology 2018;1:159-162 (in Russ).
Damle B, Duczynski G, Jeffers BW, et al. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther 2014;36(2):236-44.
Lokshin K.L. Comparative characteristics of Sildenafil and other type 5 phosphodiesterase inhibitors in the treatment of patients with erectile dysfunction (literature review). Russian medical journal. 2013; 18: 936-939 (in Russ).
Gamidov S.I., Ovchinnikov R.I., Popova A.Yu., Izhbaev S.Kh. Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future. Urology 2017;1:103-108 (in Russ).
Rubio-Aurioles E., Porst H., Kim E.D., Montorsi F., Hackett G., Morales A.M., Stuckey B., Būttner H., West T.M., Huynh N.N., Lenero E., Burns P., Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9:1418–1429.
Gafarov R.R. Minimally invasive technologies in the surgical treatment of benign prostatic hyperplasia. Journal of biomedicine and practice. 2023;8(3):423-429 (in Russ).
Porst H., McVary K.T., Montorsi F. et al. Effects of once-daily signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009; Oct; 56(4):727–735.
Giyasov S.I., Gafarov R.R., Shodmonova Z.R., Mukhtarov S.T., Akilov F.A. The role of systematization of postoperative complications in assessing the efficiency and safety of surgical methods for the treatment of benign prostatic hyperplasia. Urologiia. 2022;3:83-91.
Crowe SM, Streetman DS. Vardenafil treatment for erectile dysfunction. Ann Pharmacother. 2004 Jan;38(1):77-85.
Korneev I.A. Levitra® (orally dispersible tablet) is an innovative drug for the treatment of patients with erectile dysfunction. Urology 2013; 2:64-68 (in Russ).
Sanford M. Vardenafil orodispersible tablet. Drugs. 2012; 72(1):87–98.
Hatzimuratidis et al. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism, 2019.
Kang SG, Kim JJ. Udenafil: efficacy and tolerability in the management of erectile dysfunction. Ther Adv Urol. 2013 Apr;5(2):101-10.
Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946–953.
Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848–54.
Corona G., Rastrelli G., Burri A., Jannini E.A., Maggi M. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf 2016;15:237-47.
Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, et al. A randomized, double-blind, placebocontrolled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122-33.
Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother. 2013;47(10):1312-20.
Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF, Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553-7.
Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7(5):1928-36.
Peak TC, Yafi FA, Sangkum P, Hellstrom WJ. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015;20(2):263-75.
Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014;32(1):18-27.
Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5(11):2672-80.
Lee JY, Cho SY, Oh CY, et al. Efficacy and safety of combination therapy with mirodenafil and alpha1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res 2011;23(6):249-56.
Wang K, Ding J, Li X, Guo W, Zhu X, Su Y, Sun L, Zhou H, Ding L. Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects. Eur J Pharm Sci. 2022; 1(175):106213.
Liang B, Wang J, Bai N, Chi Y, Wang R, Cai Y. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers. Clin Pharmacol Drug Dev. 2022;11(10):1184-1190.
Sweetnam P, Campbell S, Grogan M, et al. SLx-2101, a novel long-acting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: in vivo and in vitro studies [abstract no. 51]. J Sex Med 2006; 3 Suppl. 1: 30 60.
Prince WT, Campbell AS, Tong W, et al. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Sex Med 2006; 3 Suppl. 1: 29-30.
Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-50.
Qian H, Chen Q, Liang L, Zou Y, Pu H, Xin L, Song R, Li T, Zhu H, Wang Y, Tian G, Shen J, Jiang H, Yu C, Wang Z, Jia J. A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. Drug Des Devel Ther. 2021; 6(15):2947-2959.
Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex Med Rev. 2018;6(2):242-252.
Barroso F, Ribeiro JC, Miranda EP. Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review. J Ophthalmic Vis Res. 2021. 29;16(2):248-259.
Mostafa T, Alghobary MF. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight. Sex Med Rev. 2022;10(3):392-402
Wanjari M, Late S. Use of Sildenafil in young adults: a growing health problem. Pan Afr Med J. 2023;1(44):113.
Lui JL, Shaw NM, Abbasi B, Hakam N, Breyer BN. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database. Andrology. 2023;11(7):1408-1417.
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.
Shodmonova Z.R., Gafarov R.R., Allazov S.A., Giyasov S.I. Phosphodesterase type 5 inhibitors-clinical efficiency and role in therapy for erectile dysfunction. Urologiia. 2021;2:135-140.
Статья поступила в редакцию 10.05.2024; одобрена после рецензирования 21.06.2024; принята к публикации 29.06.2024.
The article was submitted 10.05.2024; approved after reviewing 21.06.2024; accepted for publication 29.06.2024.
Информация об авторе:
Гафаров Рушен Рефатович - к.м.н., доцент кафедры хирургических болезней №1, трансплантологии и урологии Самаркандского государственного медицинского университета, Самарканд, Узбекистан. Е-mail: rushen.gafarov@bk.ru, https://orcid.org/0000-0002-1805-6366
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Автор декларирует отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Information about the authors:
Rushen R. Gafarov - PhD, Associate Professor at the Department of Surgical Diseases №1, Transplantology and Urology of Samarkand State Medical University. Samarkand, Uzbekistan; E-mail: rushen.gafarov@bk.ru, https://orcid.org/0000-0002-1805-6366
Sources of funding: The work did not receive any specific funding.
Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.
